Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, and CAR-T cell therapy research.
Gut microbiome and immune checkpoint inhibitor toxicity
A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks
ESMO basic requirements for AI-based biomarkers in oncology (EBAI)
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Clinical and translational attributes of immune-related adverse events
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
Long-Term Survival in Patients With Advanced Melanoma
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
Adjuvant treatment with anti‐ <scp>PD</scp> ‐1 in acral melanoma: A nationwide study
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
Physical activity and checkpoint inhibition: association with toxicity and survival
Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review
PRAME Staining in Sinonasal Mucosal Melanoma: A Single-Center Experience